Abstract
Recent reports that bone marrow angiogenesis is increased in multiple myeloma prompted us to examine plasma concentrations of angiogenic growth factors and to elucidate their clinical and biological significance. In 45 cases including 36 cases of multiple myeloma and 9 cases of monoclonal gammopathies of undetermined significance (MGUS), plasma concentrations of basic fibroblast growth factor (FGF‐2) and vascular endothelial growth factor (VEGF) were evaluated. FGF‐2 was significantly elevated in 25 out of 45 (56%) of the patients with multiple myeloma compared with control subjects (median 9.01 pg/ml vs. 1.58 pg/ml, P<0.0001). The 25 cases were all active multiple myeloma, and none of the non‐active myeloma and MGUS patients showed a high FGF‐2 level. VEGF level was also elevated in 26 out of 45 patients (58%) compared with control subjects (median 42.0 pg/ml vs. 15.8 pg/ml, P<0.0001 for VEGF). VEGF concentration was high in 20 active myelomas, but also in one non‐active myeloma and five MGUS. Elevation of FGF‐2 level was associated with β2‐microglobulin level, anemia and bone marrow plasma cell percentage, which represent disease activity. Interestingly, none of five Bence‐Jones type myelomas, including four clinically active cases, revealed a high plasma FGF‐2 level, while all of them showed a high VEGF level. In all five responders, the plasma FGF‐2 levels were significantly decreased after chemotherapy. FGF‐2 was immunohistochemically detected in the bone marrow myeloma cells of the patients with high plasma FGF‐2 level. We conclude that plasma concentration of FGF‐2 can be a useful indicator of disease activity.
Keywords: Multiple myeloma, Basic fibroblast growth factor, Angiogenesis, Vascular endothelial growth factor, Disease activity
Full Text
The Full Text of this article is available as a PDF (9.6 MB).
REFERENCES
- 1.Oken , M. M.Multiple myeloma: prognosis and standard treatment . Cancer Invest. , 15 , 57 – 64 ( 1997. ). [DOI] [PubMed] [Google Scholar]
- 2.Alexanian , R. and Dimopoulos , M.The treatment of multiple myeloma . N. Engl. J. Med. , 330 , 484 – 489 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 3.Kawano , M. , Hirano , T. , Matsuda , T. , Taga , T. , Horii , Y. , Iwato , K. , Asaoku , H. , Tang , B. , Tanabe , O. , Tanaka , H. , Kuramoto , A. and Kishimoto , T.Autocrine generation and essential requirement of BSF‐2/IL‐6 for human multiple myeloma . Nature , 332 , 83 – 85 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 4.Vacca , A. , Ribiatti , D. , Roncali , L. , Ranieri , G. , Serio , G. , Silvestris , F. and Dommacco , F.Bone marrow angiogenesis and progression in multiple myeloma . Br. J. Haematol. , 87 , 503 – 508 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 5.Vacca , A. , Ribiatti , D. , Roncali , L. and Dommacco , F.Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies . Leuk. Lymphoma , 20 , 27 – 38 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 6.Vacca , A. , Loreto , M. D. , Ribiatti , D. , Stefano , R. D. , Gadaleta‐Caldarola , G. , Lodice , G. , Caloro , D. and Dommacco , F.Bone marrow of patients with active myeloma: angiogensis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44 . Am. J. Hematol. , 50 , 9 – 14 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 7.Asahara , T. , Bauters , C. , Zheng , L. P. , Takeshita , S. , Bunting , S. , Ferrara , N. , Symes , J. F. and Isner , J. M.Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo Circulation , 92 , 365 – 371 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 8.Fujimoto , K. , Ichimori , Y. , Kakizoe , T. , Okajima , E. , Sakamoto , H. , Sugimura , T. and Terada , M.Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma . Biochem. Biophys. Res. Commun. , 180 , 386 – 392 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 9.Dirix , L. Y. , Vermeulen , P. B. , Pawinski , A. , Prove , A. , Benoy , L , De Footer , C. , Martin , M. and Van Oosterom , A. T.Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients . Br. J. Cancer , 76 , 238 – 243 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Menzel , T. , Rahman , Z. , Calleja , E. , White , K. , Wilson , E. L. , Wieder , R. and Gabrilove , J.Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine . Blood , 87 , 1056 – 1063 ( 1996. ). [PubMed] [Google Scholar]
- 11.Salven , P. , Teerenhovi , L. and Joensuu , H.A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non‐Hodgkin's lymphoma . Blood , 94 , 3334 – 3339 ( 1999. ). [PubMed] [Google Scholar]
- 12.Aguayo , A. , Kantarjian , H. , Manshouri , T. , Gidel , C. , Estey , E. , Thomas , D. , Roller , C. , Estrov , Z. , O'Brien , S. , Keating , M. , Freireich , E. and Albitar , M.Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes . Blood , 96 , 2240 – 2245 ( 2000. ). [PubMed] [Google Scholar]
- 13.Vacca , A. , Ribiatti , D. , Presta , M. , Minischetti , M. , Iurlaro , M. , Ria , R. , Albini , A. , Bussolino , F. and Dommacco , F.Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase‐2 secretion parallel progression of human multiple myeloma . Blood , 93 , 3064 – 3073 ( 1999. ). [PubMed] [Google Scholar]
- 14.Bellamy , W. T. , Richter , L. , Frutiger , Y. and Grogan , T. M.Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies . Cancer Res. , 59 , 728 – 733 ( 1999. ). [PubMed] [Google Scholar]
- 15.Salven , P. , Orpana , A. , Teerenhovi , L. and Joensuu , H.Simultaneous elevation of the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non‐Hodgkin lymphoma: a single‐institution study of 200 patients . Blood , 96 , 3712 – 3718 ( 2000. ). [PubMed] [Google Scholar]
- 16.Durie , B. G. M. and Salmon , S. E.A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival . Cancer , 36 , 842 – 854 ( 1975. ). [DOI] [PubMed] [Google Scholar]
- 17.Banks , R. E. , Forbes , M. A. , Kinsey , S. E. , Stanley , A. , Ingham , E. , Walters , C. and Selby , P. J.Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology . Br. J. Cancer , 77 , 956 – 964 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Perez‐Atyde , A. R. , Sallan , S. E. , Tedrow , U. , Connors , S. , Allred , E. and Folkman , J.Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia . Am. J. Pathol. , 150 , 815 – 821 ( 1997. ). [PMC free article] [PubMed] [Google Scholar]
- 19.Tricot , G.New insights into role of microenvironment in multiple myeloma . Lancet , 355 , 248 – 250 ( 2000. ). [DOI] [PubMed] [Google Scholar]
- 20.Rajkumar , S. V. , Leong , T. , Roche , P. C. , Fonseca , R. , Dispenzieri , A. , Lacy , M. Q. , Lust , J. A. , Witzig , T. E. , Kyle , R. A. , Gertz , M. A. and Greipp , P. R.Prognostic value of bone marrow angiogenesis in multiple myeloma . Clin. Cancer Res. , 6 , 3111 – 3116 ( 2000. ). [PubMed] [Google Scholar]
- 21.Chesi , M. , Nardini , E. , Brents , L. A. , Schroch , E. , Ried , T. , Kuehl , M. W. and Bersagel , P. L.Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 . Nat. Genet. , 16 , 260 – 264 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Plowright , E. E. , Li , Z. , Bergsagel , L. , Chesi , M. , Barber , D. L. , Branch , D. R. , Hawley , R. G. and Stewart , A. K.Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis . Blood , 95 , 992 – 998 ( 2000. ). [PubMed] [Google Scholar]
- 23.Hattori , Y. , Odagiri , H. , Katoh , O. , Sakamoto , H. , Morita , T. , Shimotohno , K. , Tobinai , K. , Sugimura , T. and Terada , M.K‐sam‐related gene, N‐sam, encodes fibroblast growth factor receptor and is expressed in T‐lymphocytic tumors . Cancer Res. , 52 , 3367 – 3371 ( 1992. ). [PubMed] [Google Scholar]
- 24.Raimondo , F. D. , Azzaro , M. P. , Palumbo , G. A. , Bagnato , S. , Giustolisi , G. , Floridia , P. M. , Sortino , G. and Giustolisi , R.Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood . Haematologica , 85 , 800 – 805 ( 2000. ). [PubMed] [Google Scholar]
- 25.Otsuki , T. , Yamada , O. , Yata , K. , Sakaguchi , H. , Kurebayashi , J. , Nakazawa , N. , Taniwaki , M. , Yawata , Y. and Ueki , A.Expression of fibroblast growth factor and FGF‐receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32.3) and FGFR3 translocation . Int. J. Oncol. , 15 , 1205 – 1212 ( 1999. ). [DOI] [PubMed] [Google Scholar]
- 26.Borset , M. H. , Hansen , H. , Seidel , C. , Sundan , A. and Waage , A.Hepatocyte growth factor and its receptor c‐MET in multiple myeloma . Blood , 88 , 3998 – 4004 ( 1996. ). [PubMed] [Google Scholar]
- 27.Sezer , O. , Jakob , C. , Eucker , J. , Niemoller , K. , Gatz , F. , Wernecke , K.‐D. and Possinger , K.Serum levels of the angiogenic cytokines basic fibroblast growth factor, vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma . Eur. J. Haematol. , 66 , 83 – 88 ( 2001. ). [DOI] [PubMed] [Google Scholar]